Product image of Levesialle Continu (Ethinylestradiol, Levonorgestrel | Lactose) supplied by GNH India

Levesialle Continu

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose
Origin:
EU

Levesialle Continu (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol, the active ingredient in Levesialle Continu, is a combined oral contraceptive presented as a tablet for oral use. It works together with levonorgestrel to prevent pregnancy in women of reproductive age and to regulate menstrual cycles when prescribed. The formulation includes lactose as an inactive filler.

GNH India supplies Levesialle Continu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with consistent quality assurance and regulatory compliance across EU markets. The company ensures timely delivery and supports local regulatory submissions.

Manufacturer / TM Owner

Exeltis Germany Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levesialle Continu, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent ovulation.
  • Contraception: prevents pregnancy by inhibiting ovulation and altering cervical mucus.
  • Menstrual cycle regulation: provides more predictable periods and reduces menstrual flow when used continuously.
  • Acne treatment: improves acne vulgaris in women by reducing androgenic activity.

How It Works

  • Ethinylestradiol and levonorgestrel bind to estrogen and progesterone receptors, respectively, suppressing the hypothalamic release of gonadotropin‑releasing hormone. This reduces follicle‑stimulating hormone and luteinizing hormone secretion, inhibiting ovulation. The progestin also thickens cervical mucus and alters the endometrial lining, creating an environment unsuitable for fertilisation and implantation.

Side Effects

Levesialle Continu may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea
  • Headache
  • Breast tenderness
  • Spotting between periods
  • Mild weight gain
  • Mood changes

Serious or Rare Side Effects

  • Deep vein thrombosis or pulmonary embolism
  • Stroke or transient ischemic attack
  • Myocardial infarction
  • Severe allergic reaction (anaphylaxis)
  • Liver tumor or cholestatic jaundice
  • Hyperglycaemia in diabetic patients

Precautions & Warnings

Before prescribing Levesialle Continu, clinicians should evaluate individual risk factors and counsel patients on safe use.

  • Assess cardiovascular risk: review history of thromboembolic disorders before initiating therapy.
  • Avoid smoking: patients over 35 who smoke should not use combined oral contraceptives.
  • Monitor blood pressure: check regularly during treatment.
  • Consider liver function: adjust or avoid use in significant hepatic impairment.
  • Review drug interactions: assess concomitant medications that may affect hormone levels.
  • Store at room temperature: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Levesialle Continu can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): may reduce contraceptive efficacy.
  • HIV protease inhibitors: decrease hormone levels, increasing risk of contraceptive failure.
  • Strong enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): increase hormone metabolism, reducing effectiveness.

Moderate Interactions (Monitor Closely)

  • Rifampin and other broad‑spectrum antibiotics: may lower hormone concentrations.
  • St. John’s wort: enzyme inducer that can reduce contraceptive efficacy.
  • Diuretics: may increase the risk of hypertension while on combined oral contraceptives.

Frequently Asked Questions

Levesialle Continu is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It may also be prescribed to help regulate menstrual cycles and to treat acne vulgaris when hormonal control is desired.

Ethinylestradiol is a synthetic estrogen that binds to estrogen receptors, providing negative feedback to the hypothalamus and pituitary gland. This suppresses the release of follicle‑stimulating hormone and luteinizing hormone, thereby preventing the ovulatory surge required for egg release.

The dosing regimen for Levesialle Continu is determined by the prescribing clinician. Typically, the product is taken once daily for a defined cycle, but the exact number of tablets and any hormone‑free interval are set according to the individual’s medical assessment.

Levesialle Continu is classified as pregnancy category X, meaning it is contraindicated in pregnant women because it may harm the fetus. It is also not recommended for breastfeeding mothers, as hormonal exposure can affect milk production and infant development.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levesialle Continu contains the standard dose of ethinylestradiol paired with levonorgestrel, a progestin with a well‑established safety profile. Compared with newer progestins, levonorgestrel offers reliable ovulation inhibition and a predictable bleeding pattern, while maintaining a comparable risk‑benefit balance.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Levesialle Continu is taken orally, usually with water, at the same time each day. Patients should follow the prescriber’s schedule, which often involves a series of active tablets followed by a hormone‑free interval, if applicable.

Serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, severe allergic reactions, and liver disorders. Patients should seek immediate medical attention if they experience unexplained leg pain, chest pain, shortness of breath, severe abdominal pain, or signs of an allergic reaction.

Contraindications include women who are pregnant, have a history of thromboembolic disease, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or who smoke cigarettes and are over 35 years of age. A thorough medical review is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT